DARE - Daré Bioscience, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Daré Bioscience, Inc.

3655 Nobel Drive
Suite 260
San Diego, CA 92122
United States

Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Ms. Sabrina Martucci JohnsonPres, CEO, Sec. & DirectorN/AN/A1967
Ms. Lisa Walters-HoffertChief Financial OfficerN/AN/A1959
Mr. Mark WaltersVP of OperationsN/AN/A1955
Ms. MarDee J. Haring-LaytonVP of Accounting & Fin.N/AN/A1976
Dr. David FriendChief Scientific OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy. The company has license agreement with ADVA-Tec, Inc. to develop and commercialize Ovaprene for human contraceptive use; and license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company is headquartered in San Diego, California.

Corporate Governance

Daré Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.